[Subcutaneous therapy of hairy cell leukemia with 2-chlorodeoxyadenosine].
The efficacy of subcutaneous 2-chlorodeoxyadenosine (2-CdA) was explored in eight patients with symptomatic hairy cell leukemia. This study is an interim report of a larger ongoing internordic multicentre clinical trial of subcutaneous 2-CdA in patients with hairy cell leukemia. The present results strongly indicate that subcutaneous therapy with 2-CdA induces an impressive therapeutic response which is fully comparable to the traditional continuous intravenous treatment with 2-CdA. The morbidity was acceptable, and the patient compliance to subcutaneous 2-CdA was excellent. In terms of the rate of complete remission (70-90%), therapy with 2-CdA in hairy cell leukemia is superior to any other drug. Consequently, 2-CdA is expected soon to displace both interferon alpha and deoxycoformycin as first line therapy in hairy cell leukemia. A long follow-up time is required, though, to decide whether 2-CdA is capable of curing patients with hairy cell leukemia.
Nielsen
O J
OJ
Medicinsk haematologisk afdeling L, Amtssygehuset i Herlev.
Hippe
E
E
Priø
T K
TK
Juliusson
G
G
D000328:Adult; D017338:Cladribine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D017338:Cladribine
Subkutan behandling af hårcelleleukaemi med 2-klordeoxyadenosin.